FDA Inspection 1201486 — GenIbet Biopharmaceuticals, S.A.
The FDA completed an inspection of GenIbet Biopharmaceuticals, S.A. on Jan 31, 2023 in Oeiras. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Biologics.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Jan 31, 2023
- Fiscal Year
- 2023
- Product Type
- Biologics
- Project Area
- Vaccines and Allergenic Products
- Location
- Oeiras (Portugal)